Home Authors Posts by DrugPatentWatch.com Drug Patent Expirations

DrugPatentWatch.com Drug Patent Expirations

19 POSTS 0 COMMENTS

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations body { font-family:Calibri, tahoma, arial, sans-serif;}table { font-size:12px; font-family:Calibri, tahoma, arial, sans-serif; border-collapse:collapse; margin: 0px auto;}.xsnazzy h1, .zsnazzy h1 { margin:0; font-size:1.2em; padding:0 10px 5px 10px; border-bottom:1px solid #444; }.xsnazzy { background: transparent; margin:0 3px;}.xtop, .xbottom { display:block; background:transparent; font-size:1px; }.xb1, .xb2, .xb3, .xb4 { display:block; overflow:hidden; }.xb1, .xb2, .xb3 { height:1px; }.xb2, .xb3, .xb4 { background:#fff; border-left:1px solid #444; border-right:1px solid #444; }.xb1 { margin:0 5px; background:#444; }.xb2 { margin:0 3px; border-width:0 2px; }.xb3 { margin:0 2px; }.xb4 { height:2px; margin:0 1px;}.xboxcontent { display:block; border:0 solid #444; border-width:0 1px; height:auto; }* html .xboxcontent { height:1px; } td { padding:3px; } tr { border:.5pt; background-color:#FFF; }
Who are the leading pharmaceutical patent challengers? A report on
Paragraph IV challenges
ADVERTISE HERE 

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Simple flat-rate database subscription plans

Ultimate PlanPremium PlanBasic Plan
One year$1,995 Subscribe$1,795 Subscribe$1,095 Subscribe
One month$525 Subscribe$425 Subscribe$325 Subscribe
48 hours$95 Subscribe$75 Subscribe
Plan comparison    Site tour    Contact

Drug Patent Expirations for May 17 2012

TradenameApplicantGeneric NamePatent Number Patent Expiration
PLAVIXSanofi Aventis Usclopidogrel bisulfate4,847,265*PEDMay 17, 2012

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Fills Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations body { font-family:Calibri, tahoma, arial, sans-serif;}table { font-size:12px; font-family:Calibri, tahoma, arial, sans-serif; border-collapse:collapse; margin: 0px auto;}.xsnazzy h1, .zsnazzy h1 { margin:0; font-size:1.2em; padding:0 10px 5px 10px; border-bottom:1px solid #444; }.xsnazzy { background: transparent; margin:0 3px;}.xtop, .xbottom { display:block; background:transparent; font-size:1px; }.xb1, .xb2, .xb3, .xb4 { display:block; overflow:hidden; }.xb1, .xb2, .xb3 { height:1px; }.xb2, .xb3, .xb4 { background:#fff; border-left:1px solid #444; border-right:1px solid #444; }.xb1 { margin:0 5px; background:#444; }.xb2 { margin:0 3px; border-width:0 2px; }.xb3 { margin:0 2px; }.xb4 { height:2px; margin:0 1px;}.xboxcontent { display:block; border:0 solid #444; border-width:0 1px; height:auto; }* html .xboxcontent { height:1px; } td { padding:3px; } tr { border:.5pt; background-color:#FFF; }
Pharmaceutical Industry Intelligence

ADVERTISE HERE 

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Simple flat-rate database subscription plans

Ultimate PlanPremium PlanBasic Plan
One year$1,995 Subscribe$1,795 Subscribe$1,095 Subscribe
One month$525 Subscribe$425 Subscribe$325 Subscribe
48 hours$95 Subscribe$75 Subscribe
Plan comparison    Site tour    Contact

Drug Patent Expirations for May 14 2012

TradenameApplicantGeneric NamePatent Number Patent Expiration
AGGRASTATMedicuretirofiban hydrochloride5,292,756May 14, 2012

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Fills Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations body { font-family:Calibri, tahoma, arial, sans-serif;}table { font-size:12px; font-family:Calibri, tahoma, arial, sans-serif; border-collapse:collapse; margin: 0px auto;}.xsnazzy h1, .zsnazzy h1 { margin:0; font-size:1.2em; padding:0 10px 5px 10px; border-bottom:1px solid #444; }.xsnazzy { background: transparent; margin:0 3px;}.xtop, .xbottom { display:block; background:transparent; font-size:1px; }.xb1, .xb2, .xb3, .xb4 { display:block; overflow:hidden; }.xb1, .xb2, .xb3 { height:1px; }.xb2, .xb3, .xb4 { background:#fff; border-left:1px solid #444; border-right:1px solid #444; }.xb1 { margin:0 5px; background:#444; }.xb2 { margin:0 3px; border-width:0 2px; }.xb3 { margin:0 2px; }.xb4 { height:2px; margin:0 1px;}.xboxcontent { display:block; border:0 solid #444; border-width:0 1px; height:auto; }* html .xboxcontent { height:1px; } td { padding:3px; } tr { border:.5pt; background-color:#FFF; }
Who are the leading pharmaceutical patent challengers? A report on
Paragraph IV challenges
ADVERTISE HERE 

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Simple flat-rate database subscription plans

Ultimate PlanPremium PlanBasic Plan
One year$1,995 Subscribe$1,795 Subscribe$1,095 Subscribe
One month$525 Subscribe$425 Subscribe$325 Subscribe
48 hours$95 Subscribe$75 Subscribe
Plan comparison    Site tour    Contact

Drug Patent Expirations for May 11 2012

TradenameApplicantGeneric NamePatent Number Patent Expiration
ALLEGRASanofi Aventis Usfexofenadine hydrochloride6,187,791May 11, 2012
ALLEGRASanofi Aventis Usfexofenadine hydrochloride6,399,632May 11, 2012
CHILDREN'S ALLEGRA ALLERGYSanofi Aventis Usfexofenadine hydrochloride6,187,791May 11, 2012
CHILDREN'S ALLEGRA ALLERGYSanofi Aventis Usfexofenadine hydrochloride6,399,632May 11, 2012
CHILDREN'S ALLEGRA HIVESSanofi Aventis Usfexofenadine hydrochloride6,187,791May 11, 2012
CHILDREN'S ALLEGRA HIVESSanofi Aventis Usfexofenadine hydrochloride6,399,632May 11, 2012

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Fills Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations body { font-family:Calibri, tahoma, arial, sans-serif;}table { font-size:12px; font-family:Calibri, tahoma, arial, sans-serif; border-collapse:collapse; margin: 0px auto;}.xsnazzy h1, .zsnazzy h1 { margin:0; font-size:1.2em; padding:0 10px 5px 10px; border-bottom:1px solid #444; }.xsnazzy { background: transparent; margin:0 3px;}.xtop, .xbottom { display:block; background:transparent; font-size:1px; }.xb1, .xb2, .xb3, .xb4 { display:block; overflow:hidden; }.xb1, .xb2, .xb3 { height:1px; }.xb2, .xb3, .xb4 { background:#fff; border-left:1px solid #444; border-right:1px solid #444; }.xb1 { margin:0 5px; background:#444; }.xb2 { margin:0 3px; border-width:0 2px; }.xb3 { margin:0 2px; }.xb4 { height:2px; margin:0 1px;}.xboxcontent { display:block; border:0 solid #444; border-width:0 1px; height:auto; }* html .xboxcontent { height:1px; } td { padding:3px; } tr { border:.5pt; background-color:#FFF; }
Journal of Commercial Biotechnology

ADVERTISE HERE 

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Simple flat-rate database subscription plans

Ultimate PlanPremium PlanBasic Plan
One year$1,995 Subscribe$1,795 Subscribe$1,095 Subscribe
One month$525 Subscribe$425 Subscribe$325 Subscribe
48 hours$95 Subscribe$75 Subscribe
Plan comparison    Site tour    Contact

Drug Patent Expirations for May 9 2012

TradenameApplicantGeneric NamePatent Number Patent Expiration
CRIXIVANMerck Sharp Dohmeindinavir sulfate5,413,999May 9, 2012

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Fills Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations body { font-family:Calibri, tahoma, arial, sans-serif;}table { font-size:12px; font-family:Calibri, tahoma, arial, sans-serif; border-collapse:collapse; margin: 0px auto;}.xsnazzy h1, .zsnazzy h1 { margin:0; font-size:1.2em; padding:0 10px 5px 10px; border-bottom:1px solid #444; }.xsnazzy { background: transparent; margin:0 3px;}.xtop, .xbottom { display:block; background:transparent; font-size:1px; }.xb1, .xb2, .xb3, .xb4 { display:block; overflow:hidden; }.xb1, .xb2, .xb3 { height:1px; }.xb2, .xb3, .xb4 { background:#fff; border-left:1px solid #444; border-right:1px solid #444; }.xb1 { margin:0 5px; background:#444; }.xb2 { margin:0 3px; border-width:0 2px; }.xb3 { margin:0 2px; }.xb4 { height:2px; margin:0 1px;}.xboxcontent { display:block; border:0 solid #444; border-width:0 1px; height:auto; }* html .xboxcontent { height:1px; } td { padding:3px; } tr { border:.5pt; background-color:#FFF; }
Pharmaceutical Industry Intelligence

ADVERTISE HERE 

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Simple flat-rate database subscription plans

Ultimate PlanPremium PlanBasic Plan
One year$1,995 Subscribe$1,795 Subscribe$1,095 Subscribe
One month$525 Subscribe$425 Subscribe$325 Subscribe
48 hours$95 Subscribe$75 Subscribe
Plan comparison    Site tour    Contact

Drug Patent Expirations for May 6 2012

TradenameApplicantGeneric NamePatent Number Patent Expiration
TRAVATAN ZAlcon Pharms Ltdtravoprost6,503,497May 6, 2012
TRAVATAN ZAlcon Pharms Ltdtravoprost6,849,253May 6, 2012

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Fills Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations body { font-family:Calibri, tahoma, arial, sans-serif;}table { font-size:12px; font-family:Calibri, tahoma, arial, sans-serif; border-collapse:collapse; margin: 0px auto;}.xsnazzy h1, .zsnazzy h1 { margin:0; font-size:1.2em; padding:0 10px 5px 10px; border-bottom:1px solid #444; }.xsnazzy { background: transparent; margin:0 3px;}.xtop, .xbottom { display:block; background:transparent; font-size:1px; }.xb1, .xb2, .xb3, .xb4 { display:block; overflow:hidden; }.xb1, .xb2, .xb3 { height:1px; }.xb2, .xb3, .xb4 { background:#fff; border-left:1px solid #444; border-right:1px solid #444; }.xb1 { margin:0 5px; background:#444; }.xb2 { margin:0 3px; border-width:0 2px; }.xb3 { margin:0 2px; }.xb4 { height:2px; margin:0 1px;}.xboxcontent { display:block; border:0 solid #444; border-width:0 1px; height:auto; }* html .xboxcontent { height:1px; } td { padding:3px; } tr { border:.5pt; background-color:#FFF; }
Pharmaceutical Industry Intelligence

ADVERTISE HERE 

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Simple flat-rate database subscription plans

Ultimate PlanPremium PlanBasic Plan
One year$1,995 Subscribe$1,795 Subscribe$1,095 Subscribe
One month$525 Subscribe$425 Subscribe$325 Subscribe
48 hours$95 Subscribe$75 Subscribe
Plan comparison    Site tour    Contact

Drug Patent Expirations for May 2 2012

TradenameApplicantGeneric NamePatent Number Patent Expiration
LIDODERMTeikoku Pharma Usalidocaine5,411,738May 2, 2012
LIDODERMTeikoku Pharma Usalidocaine5,601,838May 2, 2012

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Fills Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations body { font-family:Calibri, tahoma, arial, sans-serif;}table { font-size:12px; font-family:Calibri, tahoma, arial, sans-serif; border-collapse:collapse; margin: 0px auto;}.xsnazzy h1, .zsnazzy h1 { margin:0; font-size:1.2em; padding:0 10px 5px 10px; border-bottom:1px solid #444; }.xsnazzy { background: transparent; margin:0 3px;}.xtop, .xbottom { display:block; background:transparent; font-size:1px; }.xb1, .xb2, .xb3, .xb4 { display:block; overflow:hidden; }.xb1, .xb2, .xb3 { height:1px; }.xb2, .xb3, .xb4 { background:#fff; border-left:1px solid #444; border-right:1px solid #444; }.xb1 { margin:0 5px; background:#444; }.xb2 { margin:0 3px; border-width:0 2px; }.xb3 { margin:0 2px; }.xb4 { height:2px; margin:0 1px;}.xboxcontent { display:block; border:0 solid #444; border-width:0 1px; height:auto; }* html .xboxcontent { height:1px; } td { padding:3px; } tr { border:.5pt; background-color:#FFF; }
Journal of Commercial Biotechnology

ADVERTISE HERE 

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Simple flat-rate database subscription plans

Ultimate PlanPremium PlanBasic Plan
One year$1,995 Subscribe$1,795 Subscribe$1,095 Subscribe
One month$525 Subscribe$425 Subscribe$325 Subscribe
48 hours$95 Subscribe$75 Subscribe
Plan comparison    Site tour    Contact

Drug Patent Expirations for Apr 25 2012

TradenameApplicantGeneric NamePatent Number Patent Expiration
NAVSTELAlcon Pharms Ltdcalcium chloride; dextrose; magnesium chloride; oxiglutatione; potassium chloride; sodium bicarbonate; sodium chloride; sodium phosphate5,409,904Apr 25, 2012
NAVSTELAlcon Pharms Ltdcalcium chloride; dextrose; magnesium chloride; oxiglutatione; potassium chloride; sodium bicarbonate; sodium chloride; sodium phosphate5,578,578Apr 25, 2012
OPTISONGe Healthcarealbumin human5,573,751Apr 25, 2012

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Fills Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations body { font-family:Calibri, tahoma, arial, sans-serif;}table { font-size:12px; font-family:Calibri, tahoma, arial, sans-serif; border-collapse:collapse; margin: 0px auto;}.xsnazzy h1, .zsnazzy h1 { margin:0; font-size:1.2em; padding:0 10px 5px 10px; border-bottom:1px solid #444; }.xsnazzy { background: transparent; margin:0 3px;}.xtop, .xbottom { display:block; background:transparent; font-size:1px; }.xb1, .xb2, .xb3, .xb4 { display:block; overflow:hidden; }.xb1, .xb2, .xb3 { height:1px; }.xb2, .xb3, .xb4 { background:#fff; border-left:1px solid #444; border-right:1px solid #444; }.xb1 { margin:0 5px; background:#444; }.xb2 { margin:0 3px; border-width:0 2px; }.xb3 { margin:0 2px; }.xb4 { height:2px; margin:0 1px;}.xboxcontent { display:block; border:0 solid #444; border-width:0 1px; height:auto; }* html .xboxcontent { height:1px; } td { padding:3px; } tr { border:.5pt; background-color:#FFF; }
FDA Orange Book archives from 2005 to
present
ADVERTISE HERE 

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Simple flat-rate database subscription plans

Ultimate PlanPremium PlanBasic Plan
One year$1,995 Subscribe$1,795 Subscribe$1,095 Subscribe
One month$525 Subscribe$425 Subscribe$325 Subscribe
48 hours$95 Subscribe$75 Subscribe
Plan comparison    Site tour    Contact

Drug Patent Expirations for Apr 22 2012

TradenameApplicantGeneric NamePatent Number Patent Expiration
TARGRETINEisai Incbexarotene6,043,279Apr 22, 2012
TARGRETINEisai Incbexarotene6,320,074Apr 22, 2012
TARGRETINEisai Incbexarotene7,655,699Apr 22, 2012

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Fills Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations body { font-family:Calibri, tahoma, arial, sans-serif;}table { font-size:12px; font-family:Calibri, tahoma, arial, sans-serif; border-collapse:collapse; margin: 0px auto;}.xsnazzy h1, .zsnazzy h1 { margin:0; font-size:1.2em; padding:0 10px 5px 10px; border-bottom:1px solid #444; }.xsnazzy { background: transparent; margin:0 3px;}.xtop, .xbottom { display:block; background:transparent; font-size:1px; }.xb1, .xb2, .xb3, .xb4 { display:block; overflow:hidden; }.xb1, .xb2, .xb3 { height:1px; }.xb2, .xb3, .xb4 { background:#fff; border-left:1px solid #444; border-right:1px solid #444; }.xb1 { margin:0 5px; background:#444; }.xb2 { margin:0 3px; border-width:0 2px; }.xb3 { margin:0 2px; }.xb4 { height:2px; margin:0 1px;}.xboxcontent { display:block; border:0 solid #444; border-width:0 1px; height:auto; }* html .xboxcontent { height:1px; } td { padding:3px; } tr { border:.5pt; background-color:#FFF; }
Journal of Commercial Biotechnology

ADVERTISE HERE 

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Simple flat-rate database subscription plans

Ultimate PlanPremium PlanBasic Plan
One year$1,995 Subscribe$1,795 Subscribe$1,095 Subscribe
One month$525 Subscribe$425 Subscribe$325 Subscribe
48 hours$95 Subscribe$75 Subscribe
Plan comparison    Site tour    Contact

Drug Patent Expirations for Apr 25 2012

TradenameApplicantGeneric NamePatent Number Patent Expiration
NAVSTELAlcon Pharms Ltdcalcium chloride; dextrose; magnesium chloride; oxiglutatione; potassium chloride; sodium bicarbonate; sodium chloride; sodium phosphate5,409,904Apr 25, 2012
NAVSTELAlcon Pharms Ltdcalcium chloride; dextrose; magnesium chloride; oxiglutatione; potassium chloride; sodium bicarbonate; sodium chloride; sodium phosphate5,578,578Apr 25, 2012
OPTISONGe Healthcarealbumin human5,573,751Apr 25, 2012

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Fills Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.